Man et al. demonstrated that NHE1 inhibition via co-treatment with sorafenib and HMA reversed sorafenib resistance in FLT3-ITD+ AML cells, accompanied by inhibition of FLT3 signaling and the phosphorylation of STAT5, Akt, and ERK [10]. Here, SLC9A1 is linked to acute myeloid leukemia.